Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

July 2016

Coverage of Tumor Treatment Field Device for Glioblastoma


In response to inquiries from providers about coverage of tumor treating fields therapy (TTF), Harvard Pilgrim has developed a new medical policy for this treatment. TTF therapy uses alternating electric fields to inhibit cell proliferation and leads to programmed cell death in the treatment of glioblastoma, a cancer that forms from star-shaped cells in the brain called astrocytes.

Effective for dates of service beginning October 1, 2016, Harvard Pilgrim provides coverage for medically necessary TTF in the following cases:

  • For the treatment of histologically confirmed glioblastoma (GBM) in members 18 years of age or older
  • When used with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed, supra-tentorial GBM following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy
  • For the treatment of recurrent GBM when used as a monotherapy after surgical and radiation options have been exhausted

For more complete information, please refer to the Tumor Treatment Field Medical Policy.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Substance Abuse Materials Now Available Online

CLINICIAN CORNER

Medical Policy Changes for Injectable and Infusible Drugs

Coverage of Vitamin B12 Screening and Testing

Coverage of Tumor Treatment Field Device for Glioblastoma

Briviact Covered With Prior Authorization

Nuplazid Covered With Prior Authorization

New Medical Policy for H. Pylori Testing

New Medical Policy for Nucala

Tier Increase for Apidra and Apidra SoloSTAR on the Premium Formulary

Tier Increase for Edecrin on the Premium Formulary

Diagnosing and Treating Depression in Older Adults

P&T Committee Meeting Update

Specialty Pharmacy Update

OFFICE ASSISTANT

Reminder: Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator